Did you know?
ChinaBio® Group is an investment, consulting and media firm helping western life science companies achieve success in China. ChinaBio works with U.S., European and APAC companies seeking partnerships, acquisitions, novel technologies and funding in China.  

>> Learn more…

Site Search

>> Advanced Search

  Quick Search:

Free Newsletter

  Email address:

Novozymes Opens Hyaluronic Acid Plant in Tianjin

publication date: May 16, 2012
View a Printer Friendly version of this page, allowing you to print the page. Send a summary of this page to someone via email.
Novozymes Biopharma, the pharmaceutical subsidiary of Novozymes A/S, a Swedish maker of industrial enzymes, has begun selling hyaluronic acid that is made at its new Tianjin facility. Novozymes’ HA product is manufactured via a Bacillus-based process, while conventionally produced HA is derived from rooster combs or strains of Streptococcus bacteria. In comparison to its competitors’ HA, Novozymes says its HA is less prone to impurities or viral contamination. More details....

Stock Symbols: (NSDQ OMX: Copenhagen: NZYM B)

Share this with colleagues:  

This article is available for purchase - please click here for details.

Sorry... this feature or article is only available to subscribers.

>> Learn more about our subscription plans...

>> Free email newsletter...

>> Login...